hepatocellular carcinoma

Quiz

HCC Fundamentals

04/26/2022

Test your IO knowledge! Can you correctly answer these 8 questions on the management of hepatocellular carcinoma?

Test your IO knowledge! Can you...

04/26/2022

IO Learning

Clinical Images

Radiation Segmentectomy and Subsegmentectomy of Hepatocellular Carcinoma

10/21/2021

John T. Moon, MD¹; Andrew N. Tran¹; Nariman Nezami, MD²

John T. Moon, MD1; Andrew N. Tran1; N...

Dr Nezami and colleagues present 2 cases of radiation segmentectomy with yttrium-90 in 2 elderly patients with biopsy-confirmed hepatocellular carcinoma.

Dr Nezami and colleagues present...

10/21/2021

IO Learning

Clinical Images

Transarterial Chemoembolization as a Mechanism to Downstage Patients With Hepatocellular Carcinoma to Transplant Eligibility

10/20/2021

Bryan Wright, BS¹; Robert M. Cannon, MD²; Andrew J. Gunn, MD³

Bryan Wright, BS1; Robert M. Cannon,...

A 63-year-old man diagnosed with HCC was deemed an appropriate liver transplant candidate, but currently outside Milan criteria. He was referred to IR for consideration of TACE as a mechanism to downstage the patient into transplant...

A 63-year-old man diagnosed with...

10/20/2021

IO Learning

NCCN Updates Clinical Practice Guideline for Hepatobiliary Cancers

03/09/2021

Janelle Bradley

NCCN released an update to its guideline for hepatobiliary cancers, featuring updates in HCC, gallbladder cancer, intrahepatic cholangiocarcinoma, and biliary tract cancer.

NCCN released an update to its...

03/09/2021

Journal of Clinical Pathways

ENGAGING EXPERTS

High Economic Burden of HCC Treated With Loco-Regional Therapies

01/27/2021

Journal of Clinical Pathways

Videos

Post-Treatment Alpha-Fetoprotein Reduction Prognostic for Survival Outcomes in HCC

01/26/2021

Journal of Clinical Pathways

News

Using ASCO Value Framework to Compare Treatment Options for HCC

01/21/2021

Journal of Clinical Pathways

Conference Coverage

Lenvatinib Effective for Unresectable HCC in the Real-World Setting

01/16/2021

Journal of Clinical Pathways

Conference Coverage

Atezolizumab Plus Bevacizumab Unlikely to be Cost-Effective Compared With Sorafenib for HCC

01/15/2021

Journal of Clinical Pathways

Pressure Injury Mimicry in an Iso-at-Risk Nursing Home Resident on Regorafenib: Hand-Foot Skin Reaction (HFSR)

A 76-year-old male resident of a skilled nursing facility presented with large deep bilateral heel blisters consistent with stage 2 pressure injuries. His medical problems included hepato...

11/04/2019